Business · 02/09/2026Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product GENGLYCOS
Summary
The FDA has awarded a priority review voucher to Ultragenyx Pharmaceutical, Inc. for its rare pediatric disease product GENGLYCOS, which was approved on August 19, 2026, under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Health and Human ServicesOpen original release →